Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Silodosin capsules treat signs and symptoms of an enlarged prostate gland
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Study achieves primary endpoint of radiographic progression-free survival
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Transformation to pure-play Innovative Medicines company nears completion
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
